Rob Ross

Rob Ross serves as the chief executive officer of Surface Oncology. Prior to becoming CEO, he served as Surface’s chief medical officer, overseeing all clinical and regulatory operations and development efforts. Rob has the extensive biotech experience, including leading the clinical development of genetically modified cellular therapies in thalassemia and sickle cell disease at bluebird bio. Rob was also the head of oncology at bluebird, building a multifaceted oncology program, led by the anti-BCMA chimeric antigen T cell therapy (Abecma) in collaboration with Celgene. Previously, he worked at Genentech and Infinity Pharmaceuticals on both small molecule and antibody programs from Phase 1 through pivotal trials and was a faculty member at the Dana-Farber Cancer Institute, treating patients with genitourinary malignancies. Rob earned his bachelor’s degree from Stanford University, his master’s degree from Harvard Medical School, and his medical degree from Columbia University Vagelos College of Physicians and Surgeons. Rob did his residency in internal medicine at the University of California, San Francisco, and his fellowship in hematology/oncology at the combined program at the Dana Farber/Massachusetts General Hospital.